Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.080
-0.160 (-7.14%)
At close: Mar 6, 2026, 4:00 PM EST
2.110
+0.030 (1.44%)
After-hours: Mar 6, 2026, 7:49 PM EST
Moleculin Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 8.87 | 8.79 | 10.02 | 11.54 | 8.39 | 6.79 | |
| Research & Development | 15.23 | 17.73 | 19.49 | 18.97 | 14.42 | 12.76 | |
| Operating Expenses | 24.21 | 26.64 | 29.63 | 30.64 | 22.97 | 19.74 | |
| Operating Income | -24.21 | -26.64 | -29.63 | -30.64 | -22.97 | -19.74 | |
| Interest & Investment Income | 0.14 | 0.55 | 1.37 | 0.24 | 0.31 | 0.01 | |
| Other Non Operating Income (Expenses) | -27.34 | 4.33 | -1.51 | 1.38 | 6.77 | 2.37 | |
| EBT Excluding Unusual Items | -51.41 | -21.76 | -29.77 | -29.03 | -15.89 | -17.36 | |
| Pretax Income | -51.41 | -21.76 | -29.77 | -29.03 | -15.89 | -17.36 | |
| Net Income | -51.41 | -21.76 | -29.77 | -29.03 | -15.89 | -17.36 | |
| Net Income to Common | -51.41 | -21.76 | -29.77 | -29.03 | -15.89 | -17.36 | |
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 | |
| Shares Change (YoY) | 528.05% | 74.28% | 3.60% | 6.43% | 172.97% | 45.07% | |
| EPS (Basic) | -76.14 | -158.02 | -376.71 | -380.52 | -221.77 | -661.02 | |
| EPS (Diluted) | -76.14 | -158.02 | -376.71 | -380.52 | -221.77 | -661.02 | |
| Free Cash Flow | -22.45 | -23.88 | -23.72 | -27.71 | -18.97 | -18.15 | |
| Free Cash Flow Per Share | -33.25 | -173.36 | -300.10 | -363.22 | -264.69 | -691.18 | |
| EBITDA | -24.1 | -26.52 | -29.5 | -30.51 | -22.8 | -19.54 | |
| D&A For EBITDA | 0.11 | 0.13 | 0.13 | 0.13 | 0.16 | 0.2 | |
| EBIT | -24.21 | -26.64 | -29.63 | -30.64 | -22.97 | -19.74 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.